About
Inscripta was a pioneering biotechnology company known for its digital genome editing platform and the development of MAD7™, a CRISPR-based enzyme made available for licensing to researchers and enterprises worldwide. Inscripta has since joined forces with Manus to accelerate the global transition away from petrochemical, agricultural extraction, and animal husbandry-derived molecules toward sustainable bioalternatives. Together under the Manus brand, the combined platform scales biology to manufacture ingredients, materials, and chemicals that are more environmentally friendly and supply-chain resilient. Manus targets companies in industries such as cosmetics, food & beverage, agriculture, and specialty chemicals — helping them swap existing inputs for bio-based counterparts without sacrificing performance. The MAD7™ licensing program continues to serve the scientific community through madzymes.com, providing access to a high-performing genome editing enzyme. Whether for R&D teams exploring genome engineering or enterprises seeking sustainable sourcing strategies, the platform bridges cutting-edge synthetic biology with real-world industrial application.
Key Features
- Bioalternative Development: Enables companies to replace petrochemical or animal-derived ingredients with sustainable, bio-manufactured molecules at industrial scale.
- MAD7™ Genome Editing Enzyme: A proprietary CRISPR-based enzyme available for licensing, empowering researchers and biotech companies with powerful genome engineering capabilities.
- Sustainable Supply Chain Solutions: Helps industries build more resilient and environmentally responsible supply chains by integrating biomanufacturing into existing workflows.
- Cross-Industry Applications: Supports sectors including cosmetics, food & beverage, agriculture, and specialty chemicals in transitioning to bio-based sourcing.
Use Cases
- A cosmetics company replacing petroleum-derived fragrance molecules with sustainably bio-manufactured equivalents.
- A food & beverage brand sourcing bio-based flavor compounds instead of using traditional agricultural extraction.
- A biotech researcher licensing MAD7™ for CRISPR-based genome editing experiments.
- A specialty chemicals manufacturer building a more resilient, sustainable supply chain by integrating biomanufacturing.
- An enterprise sustainability team evaluating bioalternative ingredients to reduce their environmental footprint.
Pros
- Sustainability-Focused: Directly addresses the need to move away from harmful extraction methods by providing scalable bioalternatives.
- Proven Genome Editing Tools: MAD7™ is a well-regarded CRISPR enzyme made accessible to the broader research and biotech community through licensing.
- Industrial Scale: Manus/Inscripta's platform is built for real-world manufacturing deployment, not just laboratory research.
Cons
- Niche Audience: Primarily relevant to biotech, industrial chemistry, and life sciences companies — not broadly applicable to general software users.
- Brand Transition Uncertainty: The merger into Manus means some Inscripta-specific resources, documentation, and programs may be in transition or harder to locate.
Frequently Asked Questions
What happened to Inscripta?
Inscripta has merged with Manus to accelerate the development and commercialization of bioalternatives. The combined company now operates under the Manus brand at manus.bio.
What is MAD7™?
MAD7™ is a high-performance CRISPR genome editing enzyme developed by Inscripta and made available for licensing to researchers and organizations worldwide. Licensing is managed through madzymes.com.
What are bioalternatives?
Bioalternatives are sustainable versions of molecules traditionally sourced through petrochemical extraction, large-scale agriculture, or animal husbandry, produced instead via biomanufacturing processes.
Which industries does Manus (formerly Inscripta) serve?
Manus serves a wide range of industries including cosmetics, food and beverage, agriculture, and specialty chemicals — any sector looking to replace conventional ingredients with sustainable bio-based alternatives.
How can I access MAD7™ licensing?
MAD7™ licensing inquiries can be directed to the program site at madzymes.com, which continues to operate independently for genome editing enzyme licensing.
